Novo Nordisk rose more than 2.9% during the session, as JP Morgan included it in the "positive catalyst list."
I'm PortAI, I can summarize articles.
JP Morgan expects that Novo Nordisk's new weight loss drug CagriSema will achieve a weight loss effect of 25.1%, surpassing competitors Novo Nordisk's Wegovy at 14.9% and Eli Lilly's Zepbound at 20.9%, with similar side effects among the three. As a result, Novo Nordisk's U.S. stock rose over 2.9% on Monday
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments